Biotechnology

Avenzo Therapeutics' new CHRO hire is more than a personnel move; it's a critical piece of a master plan for a public debut and oncology market disruption.

As AN2 Therapeutics bets its future on novel boron-based drugs, the appointment of Dr. Cameron Trenor signals a critical shift from promise to proof.

PTC Therapeutics' Sephience isn't just another drug; it's a potential life-changer for PKU patients, promising to ease the burden of a lifelong restrictive diet.

As Mesoblast prepares its year-end webcast, investors weigh a stellar $115M Ryoncil launch against cash burn and the high-stakes progress of its next-gen therapies.

A new partnership between a top R&D center and a health sciences university aims to fuse AI with biomaterials, promising medical breakthroughs for Hong Kong.

With a new patent, a bold asset pivot, and a top-tier banking partner, PharmAla Biotech is signaling a new phase of commercial maturity in psychedelic medicine.

A proposed SXSW panel on longevity medicine forces a crucial question: Are we on the verge of restoring youth, or just drowning in promises? We look at the science.

A $1M award for a novel drug targeting mitochondrial dysfunction is more than just funding; it's a bet on a new paradigm for fighting neurodegeneration.

With federal funds backing its Phase 3 trial for a first-in-class cannabis withdrawal drug, PleoPharma offers a new model for biotech investment.

With positive Phase 1 results, AC Immune's NLRP3 inhibitor not only targets neuro-inflammation but also bolsters the company's independent strategy.

A new AI-designed eye drug gets clinical trial clearance, validating Matwings' iterative platform and signaling a major shift in biopharma R&D strategy.

Telix's impressive H1 results show more than just profit; they reveal a calculated strategy to build a global radiopharmaceutical powerhouse.

Venture builder Foresite Labs hires AstraZeneca's AI leader, Dr. Jorge Reis-Filho, in a strategic move that signals a new era for AI-driven company creation.

A new trial for refractory melanoma relies on a breakthrough manufacturing platform from NTx Bio. This is how automation is making personalized vaccines a reality.

A novel therapy that disarms rather than kills a deadly superbug offers a glimpse of a post-antibiotic future for patients with a debilitating lung disease.

An acquisition signals more than growth; it’s a strategic redesign of the clinical trial landscape, challenging giants and empowering innovation.

A simple urine test could soon detect cancer early. With $33M in fresh funding, Japanese bio-AI firm Craif is betting its tech can change U.S. healthcare.

The ALS Association's premier conference unites patients, researchers, and advocates to tackle the disease from the lab bench to the insurance appeal.

For families facing the grim prognosis of GM2 gangliosidoses, a new alliance offers a glimmer of hope, revealing the strategic interplay of academia and industry.

A top exec's move from a device giant to a drug startup signals a major shift. Charles Anderson analyzes why hardware's limits in fighting infection are now biotech's biggest opportunity.